United Kingdom and EuropeResearch and clinical trials
In adults with brittle bone disease, two-drug treatment increased bone density but did not reduce fractures
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The TOPaZ study, published in JAMA, tested two drugs together in adults with brittle bone disease. Teriparatide and zoledronic acid were compared with standard care. The study included 350 adults, most of them from the United Kingdom. The rate of new fractures was about 37% in both groups. The drugs increased bone density.
What does it mean for patients and families?
Even if bone density increases, the risk of fractures may not decrease. The finding shows that bone quality also matters.
Source
Scientific paper: Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta. JAMA, 2026. DOI: 10.1001/jama.2026.6889 · PubMed 42133304
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Osteogenesis imperfecta (brittle bone disease)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.